

## **Internet Enduring Materials Requirements – Activity Landing Page**

### **IMMUNOTHERAPY FOR PEDIATRIC LEUKEMIA PATIENTS**

#### **Presented by:**

William Slayton, MD  
Assistant Professor, Pediatric Hematology/Oncology  
University of Florida Department of Pediatrics  
UF College of Medicine

#### **Faculty Disclosure:**

Dr. Slayton has disclosed that he has no relevant financial relationships. No one else in a position to control content has any financial relationships to disclose.

#### **CME Advisory Committee Disclosure**

Conflict of interest information for the CME Advisory Committee members can be found on the following website:  
<https://cme.ufl.edu/disclosure/>.

**Release Date:** May 1, 2020

**Expiration Date:** April 30, 2022

#### **Target Audience:**

Pediatric hematologists/oncologists, pediatricians, family medicine physicians

#### **Learning Objectives:**

As a result of participation in this activity, participants should be able to:

1. Learn the story behind the current outstanding cure rates for acute lymphoblastic leukemia.
2. Understand the reasons why 10% of patients still relapse.
3. Appreciate the awesome power of immunotherapy in relapsed patients with ALL.
4. Learn of the current trials using immunotherapy to improve cure rates in newly diagnosed patients.

**Accreditation:** The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

**Credit:** The University of Florida College of Medicine designates this enduring material for a maximum of 0.25 *AMA PRA Category 1 Credit*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Contact Info:** If you have any questions, please feel free to contact William Slayton, MD, at 352.273.9126 or at [slaytwb@peds.ufl.edu](mailto:slaytwb@peds.ufl.edu).

**[Click here to listen to the lecture!](#)**